Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

• Status: Terminated
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RWTH Aachen University
• Collaborators: Bayer; CTCA; Heidelberg University
• Treatments: Angiotensin Receptor Antagonists; Telmisartan

Criteria

Inclusion Criteria:

• Men older than 18 years

• Diabetes mellitus type 2 defined according to the criteria of the American Diabetes Association Arterial hypertension defined according to the criteria of the Joint National Committtees (JNC 7)

• Given informed consent

Exclusion Criteria:

• Serve heart failure

• Serve aortic valve stenosis or hypertrophy obstructive cardiomyopathy

• Relevant cardiac arrhythmias

• Acute myocardial infarction within the last 4 weeks

• renal failure

• bilateral renal artery stenosis

• liver diseases

• primary hyperaldosteronism

• orthostatic hypotension (systolic blood pressure <100mmHg)

• hypokalemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia

• inflammatory disease

• malignant disease

• previous intolerance to AT1 receptor antagonists and/or sulfonamides

• current therapy with insulin sensitizer

• current therapy with digoxin

• known abuse of alcohol or drugs